Table 2.
Univariate and Multivariate analysis for time to treatment in the M-CLL patients
| Risk Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| MYD88 mutation | 1.873 | 1.067-3.287 | 0.029 | 2.233 | 1.233-4.045 | 0.008 |
| Binet C | 3.617 | 2.278-5.742 | < 0.001 | 3.653 | 2.244-5.944 | < 0.001 |
| TP53 disruption | 1.798 | 1.090-2.966 | 0.022 | 1.454 | 0.861-2.455 | 0.162 |
| ZAP70 ≥ 30% | 1.004 | 0.616-1.637 | 0.988 | - | - | - |
| CD38 ≥ 20% | 1.139 | 0.638-2.033 | 0.659 | - | - | - |
| NOTCH1 mutation | 2.669 | 0.651-10.946 | 0.173 | - | - | - |
| + 12 | 1.021 | 0.547-1.908 | 0.948 | - | - | - |
| ATM deletion | 1.830 | 0.886-3.779 | 0.102 | - | - | - |
HR hazards ratio; 95% CI, 95% confidence interval;